Skip to content

Author

Issac V. Cherian

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Aug 2026

Mitochondrial-ferroptotic crosstalk in diabetic Triopathy: a unifying mechanism linking retinal, renal, and neural complications.

Diabetes mellitus is a global health burden recognized by progressive microvascular complications, which comprise diabetic retinopathy, nephropathy, and neuropathy, often known as diabetic triopathy. Despite extensive research, the mechanistic convergence of multi-organ damage is not fully understood. Recent studies highlighted that ferroptosis, an iron-dependent form of regulated cell death mediated by lipid peroxidation, plays a crucial role in diabetic tissue damage. Importantly, mitochondria are key modulators of ferroptotic susceptibility because they regulate reactive oxygen species (ROS) production, iron homeostasis, and bioenergetic homeostasis. This review proposes mitochondrial-ferroptotic crosstalk as a unifying mechanistic axis associating retinal, renal, and neural complications in diabetes. We present a comprehensive overview of the molecular basis of ferroptosis through a mitochondria-centered perspective, covering key pathways such as iron homeostasis, the glutathione-GPX4 system, and emerging regulators of ferroptosis such as SLC7A11 and the FSP1-coenzyme Q axis. We also discuss shared vulnerabilities across microvascular tissues, such as mitochondrial dysfunction, iron overload, lipid peroxidation, and chronic inflammation. Tissue-specific evidence supporting ferroptosis in diabetic retinopathy, nephropathy, and neuropathy is discussed critically, with with mitochondrial impairment and redox imbalance emerging as prevalent drivers of the pathophysiology. Finally, we assess current and novel therapeutic approaches targeting the mitochondrial-ferroptotic axis, such as ferroptosis inhibitors, mitochondrial antioxidants, and iron-regulating approaches. Altogether, this integrative model identifies mitochondrial-ferroptotic crosstalk as a key pathogenic mechanism and therapeutic opportunity to mitigate multi-organ complications in diabetes.

Satyam Yadav, Issac V. Cherian, Akansha Sharma et al. · 0 citations
Review Jul 2026

Advancements in Lipid Nanotechnology for the Treatment of Triple-Negative Breast Cancer: Mechanistic Insights and Future Prospects

The high resistance to therapy, molecular heterogeneity, early metastasis, and quick drug resistance make triple-negative breast cancer (TNBC) difficult and even impossible to treat. The conventional chemotherapy is highly toxic, not specifically targeting the tumor, and has limited efficacy, so more sophisticated delivery mechanisms are required. To overcome these shortcomings, lipid nanotechnology is provided as a controlled, targeted, and multifunctional drug delivery system. This review outlines the recent developments of lipid nanoparticles for TNBC, including liposomes, solid lipid nanoparticles, nanostructured lipid carriers, lipidpolymer hybrids, ionizable lipid nanoparticles, and biomimetic vesicles. These systems enable improved tumor targeting and delivery of chemotherapeutics, gene editing agents, and combination therapeutics. Rational design, targeting strategies, modulation of the tumor microenvironment, targeting cancer stem cells, and breaking multidrug resistance are highlighted. Pharmacokinetic, safety, manufacturing, regulatory, and translational issues are discussed, along with pre-clinical and emerging clinical evidence. Lastly, future directions are suggested to help develop modular, precise, and clinically scalable lipid nanoparticle systems for effective management of TNBC.

Issac V. Cherian, Harpreet Kaur, Kamre Aalam et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.